Follow the ArriVent Biopharma, Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €1.4bn. The latest transaction was reported on 3 February 2026 (Cession). Among the most active insiders: LaChapelle Robin. The full history is accessible without an account.
9
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€11m
1 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate ArriVent Biopharma, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$44.60.
15Σ signal
Buys n/a€11m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
ArriVent Biopharma, Inc. is a biopharmaceutical company focused on developing innovative treatments for respiratory diseases. It is listed on NASDAQ under the ticker XNAS.